Randomized Phase II Study of Nivolumab with or Without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma
Alliance A091401 has pre-registered a sufficient number of patients in all cohorts to meet its enrollment goal. Therefore, EFFECTIVE IMMEDIATELY, Wednesday, September 5, 2018, A091401 will be temporarily suspended to enrollment until further notice. Patients who are currently pre-registered can proceed to registration, if eligible.
As of Update #06, patient enrollment will be facilitated using the Slot Reservation System. Prior to discussing protocol entry with the patient, all site staff must contact MCC to ensure that a slot on the correct cohort is available to the patient. Once a slot reservation confirmation is obtained, site staff may then proceed to consent and pre-register the patient. Once a patient is pre-registered, specimens should be submitted for central pathology review. There will be no renewal of slots for this protocol. Therefore, pre registration must be completed within 7 calendar days of slot reservation.
As of 05/31/18 the GIST cohort has no remaining slots for patient registrations.